AdipoGen Life Sciences


CHF 65.00
In stock
AG-CR1-0042-M0055 mgCHF 65.00
AG-CR1-0042-M02525 mgCHF 240.00
More Information
Product Details
Synonyms Potassium bisperoxo (1,10-phenanthroline) oxovanadate (V)
Product Type Chemical

K[VO(O2)2C12H8N2] . 3H2O

MW 350.2 . 54.0
CAS 171202-16-7
Purity Chemicals ≥99% (51V-NMR)
Appearance Yellow to orange crystalline solid.
Solubility Soluble in DMSO (1mg/ml) or water (10mg/ml).
Identity Determined by 51V-NMR (D2O).
Smiles C1[N]2=CC=CC3=C2C2=[N]1C=CC=C2C=C3
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent protein phosphotyrosine phosphatase inhibitor [1, 2, 5].
  • Insulin receptor kinase (IRK) inducer [2].
  • Insulin mimetic in vitro and in vivo [3, 4].
  • Apoptosis inducer [6].
  • ERK inducer [7].
  • Mitogen-activated protein kinase phosphatase-1 (MKP-1) inducer [7].
  • Angiogenesis inhibitor [8].
  • PTEN inhibitor [9].
Product References
  1. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics: B.I. Posner, et al.; J. Biol. Chem. 269, 4596 (1994)
  2. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen): C.J. Band, et al.; Mol. Endocrinol. 11, 1899 (1997)
  3. Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats: J.F. Yale, et al.; Diabetes 44, 1274 (1995)
  4. In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency: A.P. Bevan, et al.; Am. J. Physiol. 268, E60 (1995)
  5. A role for tyrosine phosphorylation in both activation and inhibition of the insulin receptor tyrosine kinase in vivo: P.G. Drake, et al.; Endocrinology 137, 4960 (1996)
  6. BpV (phen) induces apoptosis of RINm5F cells by modulation of MAPKs and MKP-1: L. Rumora, et al.; BBRC 300, 877 (2003)
  7. Positive regulation of ERK activation and MKP-1 expression by peroxovanadium complex bpV (phen): L. Rumora, et al.; Cell Biol. Toxicol. 20, 293 (2004)
  8. Peroxovanadium compounds as inhibitors of angiogenesis: C. J. Doillon, et al.; Angiogenesis 3, 361 (1999)
  9. Bisperoxovanadium compounds are potent PTEN inhibitors: A.C. Schmid, et al.; FEBS Lett. 566, 35 (2004)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.